key: cord-1005696-h1sb39q5
authors: Khan, Erum; Shrestha, Ashish K.; Colantonio, Mark A.; Liberio, Richard N.; Sriwastava, Shitiz
title: Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature
date: 2021-09-05
journal: J Neurol
DOI: 10.1007/s00415-021-10785-2
sha: ac1a046931aa7a6a0ed3127fd09e63d0360db200
doc_id: 1005696
cord_uid: h1sb39q5

OBJECTIVE: To report a unique case and literature review of post COVID-19 vaccination associated transverse myelitis and with abnormal MRI findings. BACKGROUND: Coronavirus disease have been reported to be associated with several neurological manifestations such as stroke, Guillain-Barré syndrome, meningoencephalitis amongst others. There are only a few reported cases of transverse myelitis with the novel coronavirus (n-CoV-2). Here, we identify a post COVID-19 vaccination patient diagnosed with acute transverse myelitis. METHOD: A retrospective chart review of a patient diagnosed with post SARS-CoV-2 vaccination acute transverse myelitis, and a review of literature of all the reported cases of other post vaccination and transverse myelitis, from December 1st, 2010 till July 15th, 2021, was performed. CONCLUSION: To our knowledge, this is the one of early reported case of transverse myelitis and with post SARS-CoV-2 vaccination, who responded well to plasmapheresis. Further studies would be recommended to identify the underlying correlation between COVID-19 vaccination and transverse myelitis.

As the coronavirus (COVID- 19) vaccines are being distributed around the world, we are witnessing the rise of Adverse Event following Immunization (AEFI). The Vaccine Adverse Event Reporting System (VAERS) of Centers for Disease Control (CDC) has reported AEFI related to Pfizer-BioNtech, Moderna and Johnson and Johnson's COVID-19 vaccines, among which there are reported neurological complications ranging from facial palsy to stroke [1] . The predominant post-vaccination side effects are the nonspecific systemic symptoms, among which the neurological symptoms include dizziness, headache, pain, muscle spasms, myalgia and paresthesia. On some rare occasions, tremor, dysphonia, diplopia, tinnitus, seizures and reactivation of herpes zoster have been reported [2] . Other serious neurological manifestation such as stroke, Guillain-Barré syndrome, Bell's palsy, transverse myelitis and acute disseminated encephalomyelitis were also reported in the VAERS database and Medicines and Healthcare products Regulatory Agency (MHRA) from UK, COVID-19 database [1, [3] [4] [5] .

According to the analysis of the database by CDC in the first month of vaccination, there appear to be very little to no safety concerns along with respect to the causal link between these side effects and vaccination [6] . However, due to the passive surveillance, the VAERS database is subjected to reporting bias and may contain some errors. Considering the large-scale vaccination campaign and less prevalence of neurological conditions in the population, the post-vaccination neurological morbidity may be due to chance alone.

Transverse myelitis (TM) is a very uncommon condition, and rarer is the vaccine-associated TM. However, some studies have reported its occurrence following administration of other vaccines, including diphtheria, tetanus toxoids and pertussis vaccine [7] , measles, mumps, and rubella (MMR) virus vaccine [8, 9] , oral poliovirus vaccine [10] , Japanese encephalitis virus vaccine [11] , hepatitis B vaccine [12] [13] [14] , yellow fever vaccine [15, 16] , typhoid vaccine [17] , rabies vaccine [18] , and seasonal influenza virus vaccine [19] [20] [21] [22] [23] [24] [25] . In addition, only oral polio vaccine was found to have a pathogenic causal relationship while other vaccines showed a temporal relationship to TM due to a common denominator such as an adjuvant [26] .

We report a case of transverse myelitis after COVID-19 vaccination. To better identify and differentiate temporal and causal associations, AEFI should be reported with a low threshold of vigilance. As our understanding grows on fronts of disease as well as the vaccine, we will be able to better prevent and cure such dreaded outcomes.

A 67-year-old patient with a significant medical history of coronary artery disease, chronic kidney disease, neuropathy and a previous colon rupture with colostomy received her first dose of the Moderna COVID-19 vaccine on May 11th, 2021. On day one post-inoculation, she experienced bilateral upper and lower extremity weakness right more than left. 5 days later, the patient presented to the Emergency Department (ED) with complaints of symptoms described above. She described her symptoms as if she were "melting in the floor like a puddle". She also mentioned tingling in right lower extremity and difficulty in ambulating requiring assistance for walking. She denied any vision changes, difficulty in swallowing or speech, shortness of breath, chest pain, and loss of smell or taste sensation.

Initial workup revealed decreased hemoglobin 8.5 g/dL (12.0-15.5 g/dL), hematocrit 27% (normal 36-48%), platelet count 1,30,000 platelets/uL (150,000-450,000 platelets/uL), Calcium 8.4 mg/dL (8.6-10.3 mg/dL, total protein 5.8 g/dL (6-8.3 g/dL), albumin 3.2 g/dL (3.4-5.4 g/dL). Creatinine was elevated to 1.32 mg/dL (0.7-1.2 mg/dL) and D-dimer elevated to 1.28 (range < 0.5).

On arrival, she was lethargic, oriented, afebrile and vitals were stable. Physical examination demonstrated cranial nerves were intact, however, motor strength showed Medical Research Council (MRC) grade of 3/5 throughout right lower extremity and 4/5 in right upper extremity, rest of motor strength was 5/5 on MRC scale. Upper motor neuron signs were present in bilateral lower extremities with Grade 3 + reflex, positive bilateral Babinski reflex and marked loss of vibration up to the ankle. Proprioception and light touch sensation were intact.

The patient underwent a brain CT, which was unremarkable. Brain MRI revealed scattered patchy foci nonspecific for white matter signal change suggestive of chronic microvascular changes no acute infarction; MRI of the cervical spine revealed hyperintense lesions in the upper cervical spine and cord edema extending from C1-C3 with patchy post-contrast enhancement (Fig. 1 ). MRI T-spine showed no intramedullary cord signal changes. Other investigations to determine the causes were done.

Cerebrospinal fluid (CSF) study revealed cell count 2, glucose 77 mg/dl, serum glucose 125 mg/dl, CSF protein 56 mg/dl, oligoclonal bands 2 in CSF and 2 in serum, with 0 isolated bands, IgG index 0.48. CSF labs yielded negative results for gram stain, culture, Cryptococcus, HSV, and VDRL, CSF-RT PCR negative for SARS-CoV-2. CSF paraneoplastic panel, autoimmune panel, flow cytometry, cytopathology were within normal limits. Patient's basic metabolic panel (BMP), lipid panel, LFTs, CK, HbA1C were within normal limits. Serum perinuclear staining antineutrophil cytoplasmic antibody (P-ANCA), ANA, myeloperoxidase antibodies, cytoplasmic-ANCA and proteinase 3 were also negative. TPO Ab and thyroglobulin Ab test were within the normal limit. Hepatitis B, RPR and HIV testing were negative. Serum MOG antibodies (Ab), HTLV I/II Ab, MTB PCR were all negative. CSF and serum NMO Anti-AQP4 AB were negative. Overall, findings were compatible with inflammatory central nervous system disorder and the presentation was thought to be from post-vaccination myelitis.

The patient was treated with IV solumedrol (IVMP) 1 g daily for 3 days. Patient showed no improvement with IV solumedrol, so Plasmapheresis (PLEX) therapy were initiated on 5/20/2021 for a 5-day period. On day 5 post-admission, the patient regained some use of her right hand, along with improved upper extremity weakness and underwent physical therapy was discharged to rehabilitation facility.

The patient began to show improvement in edema and right upper extremity weakness to the point where she was able to perform fine-motor movement. At outside Hospital, she continued to show improvements with her paresthesia and weakness. On follow-up in outpatient clinic on 07/15/2021, patient was able to ambulate without walker, motor strength was 4/5 throughout the right lower extremity, rest on the MRC motor scale was 5/5. Reflexes were 2/4, all cranial nerves were intact and marked loss of vibration was present up to the ankle. To gauge the recovery, repeat MRI scan was done and was consistent with improvement with no abnormal enhancement and improvement of prior seen abnormal hyperintensities on repeat MRI Cervical spine (Fig. 2 ). Further studies like motor and sensory evoked potentials were not done since the motor and sensory recovery was evident in outpatient examinations.

Transverse myelitis has been attributed to infectious, parainfectious, systemic autoimmune diseases, paraneoplastic, and ischemic diseases. Acute infectious transverse myelitis is usually caused by herpes simplex virus type 2, varicellazoster virus (VZV), Epstein-Barr virus (EBV) or cytomegalovirus (CMV), flaviviruses and enteroviruses [27] [28] [29] [30] [31] .

As the various infections mentioned above can trigger an immune response in our body, similarly, administration of vaccine can also induce the same response. When our immune system cannot distinguish between foreign antigens and host antigens, then it triggers autoimmunity which leads to the destruction of host cells. It is most commonly associated with environmental factors such as infectious antigens. Therefore, vaccine such as live attenuated or recombinant, can also induce autoimmunity leading to transverse myelitis [32, 33] . The following mechanisms induce autoimmunity in a person:

• The most common mechanism is molecular mimicry between infectious antigens and self-antigens [34] . • The acceleration of an ongoing autoimmune process by local activation of antigen-presenting cells and over processing of antigens induced by foreign antigens [35] . • Polyclonal activation of B lymphocytes or bystander activation which enhances cytokine production and further induce the expansion of autoreactive T-cells [36, 37] .

Acute transverse myelitis basically presents with a varied signs and symptoms of sensory, motor and autonomic dysfunction. Pathological changes in the spinal cord tract are seen on spinal imaging, as a result of focal inflammation. As this disorder can lead to debilitating effects and permanent disability, it is imperative to recognize it early and distinguish it from other neurological entities. The diagnosis of transverse myelitis involves characteristic clinical presentation of bilateral signs and symptoms with a clearly defined sensory level, in addition to evidence on neuroimaging, CSF and serologic studies [38, 39] . The inclusion criteria of transverse myelitis include the non-specific hyperintense lesion of the spinal cord and isolated grey matter involvement which makes the differential of demyelinating diseases less likely as MS affects short segments usually and concerns white matter [40, 41] .

Our case was diagnosed with transverse myelitis and fulfill the diagnostic criteria based on Transverse Myelitis Consortium Working Group [38] . Due to the absence of multiple sclerosis-like lesion in brain and oligoclonal bands in CSF along with extensive spinal cord lesion, the diagnosis of multiple sclerosis was unlikely. The imaging studies were also negative for acute disseminated encephalomyelitis and vascular lesions. Even though LETM is correlated with neuromyelitis optica, due to the absence of optic neuritis and neuromyelitis optica-IgG antibodies in serum, the diagnostic criteria are not met. Infectious cause is also ruled out due to negative serology tests along with negative CSF bacterial, viral and fungal culture results. Laboratory evidences of vasculitis and connective tissue disease were also absent. As most of the possible causes were eliminated, the abovementioned featured were attributed to post vaccination TM following SARS-CoV-2 vaccination.

The case shows close temporal association to COVID-19 vaccination with symptoms presenting and worsening within a week of first dose of Moderna Vaccine. The patient did not show any signs of COVID-19 infection before this presentation, neither were COVID-19 antibodies detected in the serum. The acute attack of transverse myelitis appeared within a week of COVID-19 vaccination, and deterioration occurred on the 12th day. This is consistent with previously reported post covid vaccinerelated TM [42, 43] . National board in UK has received reports like 22 cases of myelitis following the Pfizer-BioNtech Vaccine and 72 cases after AstraZeneca [3] [4] [5] . Whereas the VAERS CDC database reported so far total of 9 cases of transverse myelitis [1] . The marked deterioration and recovery may be cause by the immune dysregulation triggered by the vaccination. Immune dysregulation may have triggered acute transverse myelitis which may be secondary to vaccination. Neurological manifestations of both the PNS and CNS like GBS, ADEM, and ATM have been reported as vaccine induce immune-mediated events.

In our brief literature review, we reviewed cases of postvaccination cases of transverse myelitis (Refer to [13] . The most common reported vaccine-related myelitis was due to influenza vaccine (H1N1) (7 out of 20 cases) [19] [20] [21] [22] [23] [24] [25] followed by myelitis due to hepatitis B vaccine (3 of the 20 cases) [12] [13] [14] . Other causes of vaccine-related transverse myelitis included COVID-19 (SARS-CoV-2) vaccine [42] , Japanese B encephalitis [11] , Measles, Mumps and Rubella (MMR), inactivated Rabies vaccine [18] , Diphtheria, tetanus and acellular pertussis (DTaP) vaccine [7] , typhoid Vi capsular polysaccharide vaccine [17] , oral Polio vaccine (OPV) [10] , Yellow fever [15, 16] .

The predominant patient population affected were males (13 M, 7 F) with an average age of 45.3 years old with age range 7 months to 70 years. Common clinical presentations included paresthesia and sensory deficits of the lower limbs, urinary retention, paraplegia and hyperactive reflexes. MRI of this patient population revealed non-enhancing longitudinal hyperintensities and extending from the cervical spine to the thoracic spine [19] [20] [21] [22] [23] [24] rest had short segment intrameduallary spinal cord lesion, case by Joyce K et.al and Trevisani had normal MRI imaging [8, 13] . Predominant cerebral spinal fluid (CSF) analyses revealed normal white blood cells (WBC) and relatively normal glucose and elevated protein levels. Oligoclonal bands, NMO and MOG were either absent or not reported. Patients improved with IVMP and/ or PLEX therapy. All of the 20 confirmed cases showed at least partial symptomatic improvement. Four cases had only partial improvement, while 16 had near complete resolution of symptoms. Based on the literature, IVMP ± IVIG may improve the clinical course in post-vaccination acute transverse myelitis (Refer Table 1 ). These reports may not be able to identify causality as no distinction can be made between infectious and other etiology. However, a higher vigilance may provide further insights of the disease, its pathophysiology and vaccination implications. This may be determined whether any association is the cause of the higher frequency of TM observed post vaccination. It may be required to undergo risk-benefit analysis to determine the continuation of vaccination. However, as of now, vaccination seem to outweigh the risks, and a full-fledged vaccination campaign should be continued.

As the neurologic impact of the COVID-19 pandemic keeps growing, vaccine-related disorders are coming to our notice. Certainly, diligent reporting is needed for a better judgment of the actual relevance and potential risk. We will need to perform a detailed risk-benefit analysis to determine the course of action concerning vaccines if such events increase in significance. The rarity of such an occurrence should currently not deter the use of vaccines, since global vaccination represents the most important strategy to fight this pandemic. 

Services (DHHS) PHSP, Centers for Disease Control (CDC)/Food and Drug Administration (FDA) VAERS, (VAERS) 1990-07/09/2021 CWO-lD

Possible side effects after getting a COVID-19 vaccine

Medicines and healthcare products regulatory agency (MHRA) COVID-19 mRNA Pfizer-BionNTech vaccine analysis print

Medicines and healthcare products regulatory agency (MHRA) COVID-19 mRNA moderna vaccine analysis print

url? sa= t& rct= j&q= & esrc= s& source= web& cd= & cad= rja& uact= 8& ved= 2ahUK EwjOp fPmr-PyAhX QTN8K HdBvB CwQFn oECAM QAQ& url= https% 3A% 2F% 2Fass ets. publi shing. servi ce. gov. uk% 2Fgov ernme nt% 2Fupl oads% 2Fsys tem% 2Fupl oads% 2Fatt achme nt_ data% 2Ffile% 2F966 183% 2FCOV ID-19_ Astra Zeneca_ Vacci ne_ Analy sis_ Print

First month of COVID-19 vaccine safety monitoring-United States

Acute transverse myelitis in a 7 monthold boy after diphtheria-tetanus-pertussis immunization

Transverse myelitis after measles, mumps, and rubella vaccine

Transverse myelitis after measles and rubella vaccination

Extensive myelitis after oral polio vaccination: MRI features

Acute transverse myelitis after Japanese B encephalitis vaccination in a 4-year-old girl

Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report

Transverse myelitis following hepatitis B vaccination

Acute myelitis after hepatitis B vaccination

Transverse myelitis associated with yellow fever vaccination

Longitudinal myelitis associated with yellow fever vaccination

Acute transverse myelitis following typhoid vaccination

Acute transverse myelitis at the conus medullaris level after rabies vaccination in a patient with Behçet's disease

Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine

Acute transverse myelitis after influenza vaccination: magnetic resonance imaging findings

Myelopathy following influenza vaccination in inflammatory CNS disorder treated with chronic immunosuppression

Neurologic complications associated with influenza vaccination: two adult cases

Transverse myelitis with Brown-Sèquard syndrome after H1N1 immunization

Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations against seasonal and 2009 A/H1N1 influenza

Acute transverse myelitis following vaccination against H1N1 influenza: a case report

Evidence for a causal association between oral polio vaccine and transverse myelitis: a case history and review of the Literature

Herpes Simplex Virus Type 2 Myelitis: Case Report and Review of the Literature

Acute transverse myelitis complicating breakthrough varicella infection

Case report: transverse myelitis associated with Epstein-Barr virus infection

Acute transverse myelitis caused by Coxsackie virus B5 infection

Longitudinally extensive transverse myelitis in a patient infected with West Nile virus

Transverse myelitis and vaccines: a multi-analysis

Vaccination may be associated with autoimmune diseases

Molecular mimicry and auto-immunity

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

Viral infection can induce the production of autoantibodies

Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection

An approach to the diagnosis of acute transverse myelitis

The differential diagnosis of longitudinally extensive transverse myelitis

Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination

A case of longitudinally extensive transverse myelitis following vaccination against Covid-19

Agarwal V (2021) COVID-19 vaccination-associated myelitis